Published in J Virol on August 22, 2007
The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J Virol (2011) 2.44
Human cellular restriction factors that target HIV-1 replication. BMC Med (2009) 1.86
Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A. J Virol (2009) 1.53
TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm. Retrovirology (2013) 1.38
Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection. J Virol (2012) 1.35
Cellular restriction targeting viral capsids perturbs human immunodeficiency virus type 1 infection of nondividing cells. J Virol (2009) 1.32
Cyclophilin A-dependent restriction of human immunodeficiency virus type 1 capsid mutants for infection of nondividing cells. J Virol (2008) 1.30
HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. Virology (2014) 1.12
HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol (2015) 1.11
Gene-trap mutagenesis identifies mammalian genes contributing to intoxication by Clostridium perfringens ε-toxin. PLoS One (2011) 1.01
Cyclophilin A promotes HIV-1 reverse transcription but its effect on transduction correlates best with its effect on nuclear entry of viral cDNA. Retrovirology (2014) 0.98
Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol (2010) 0.95
In vivo functions of CPSF6 for HIV-1 as revealed by HIV-1 capsid evolution in HLA-B27-positive subjects. PLoS Pathog (2014) 0.94
Dynamic allostery governs cyclophilin A-HIV capsid interplay. Proc Natl Acad Sci U S A (2015) 0.86
Primate gammaretroviruses require an ancillary factor not required for murine gammaretroviruses to infect BHK cells. J Virol (2011) 0.86
Cyclophilin A stabilizes the HIV-1 capsid through a novel non-canonical binding site. Nat Commun (2016) 0.84
TRIM5 and the Regulation of HIV-1 Infectivity. Mol Biol Int (2012) 0.82
Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication. Cell Rep (2016) 0.80
SUN2 silencing impairs CD4 T cell proliferation and alters sensitivity to HIV-1 infection independently of Cyclophilin A. J Virol (2017) 0.78
Cyclophilin A-dependent restriction to capsid N121K mutant human immunodeficiency virus type 1 in a broad range of cell lines. J Virol (2013) 0.78
Gene expression analysis of a panel of cell lines that differentially restrict HIV-1 CA mutants infection in a cyclophilin a-dependent manner. PLoS One (2014) 0.75
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56
A quantitative assay for HIV DNA integration in vivo. Nat Med (2001) 8.67
Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature (1989) 8.48
Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science (1984) 8.01
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell (1993) 7.34
HIV-1 gag proteins: diverse functions in the virus life cycle. Virology (1998) 7.32
Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 7.13
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature (2004) 7.10
Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 6.82
Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell (1996) 6.74
High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res (2002) 6.64
Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med (2003) 5.97
Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature (1989) 5.86
A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol (2002) 5.49
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature (1997) 5.45
Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A (2004) 5.31
Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol (2002) 5.20
Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol (1994) 5.17
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A (2004) 5.15
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci U S A (2004) 5.08
Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A (2002) 5.02
Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci U S A (2002) 4.66
TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci U S A (2004) 4.60
A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci U S A (2002) 4.52
Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J (2003) 4.19
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci U S A (2004) 4.06
Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med (1998) 3.84
Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol (1998) 3.84
Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J Mol Biol (1997) 3.50
Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol (1998) 3.21
Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A (2003) 3.05
Proteolytic processing and particle maturation. Curr Top Microbiol Immunol (1996) 2.73
Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci U S A (2003) 2.71
p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods (1997) 2.65
Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J (2001) 2.64
Fusion from without directed by human immunodeficiency virus particles. J Virol (1994) 2.62
Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex. J Virol (2006) 2.57
Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol (2005) 2.54
Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol (2004) 2.51
Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol (2004) 2.47
Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol (2002) 2.43
Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J Virol (1996) 2.39
Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci U S A (2005) 2.21
Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J Virol (1996) 2.07
Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother (1994) 1.98
Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. EMBO J (1999) 1.98
Early steps of retrovirus replicative cycle. Retrovirology (2004) 1.94
Structural insights into the catalytic mechanism of cyclophilin A. Nat Struct Biol (2003) 1.78
Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. Virology (2000) 1.77
Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology (1996) 1.74
Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol (1998) 1.73
Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol (2006) 1.69
The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. Blood (1988) 1.56
Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J Virol (2004) 1.56
Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc Natl Acad Sci U S A (1995) 1.42
Crystal structure of cyclophilin A complexed with a binding site peptide from the HIV-1 capsid protein. Protein Sci (1997) 1.36
Cyclophilin A complexed with a fragment of HIV-1 gag protein: insights into HIV-1 infectious activity. Structure (1997) 1.34
Cells with high cyclophilin A content support replication of human immunodeficiency virus type 1 Gag mutants with decreased ability to incorporate cyclophilin A. J Virol (1998) 1.29
A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA. J Virol (2007) 1.28
Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions. J Virol (1997) 1.25
Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection. J Virol (2004) 1.14
Viral and cellular factors that regulate HIV-1 uncoating. Curr Opin HIV AIDS (2006) 1.11
Cyclophilin a plays distinct roles in human immunodeficiency virus type 1 entry and postentry events, as revealed by spinoculation. J Virol (2002) 1.05
Variable sensitivity to substitutions in the N-terminal heptad repeat of Mason-Pfizer monkey virus transmembrane protein. J Virol (2003) 1.02
Selective restriction of Nef-defective human immunodeficiency virus type 1 by a proteasome-dependent mechanism. J Virol (2006) 1.02
Maturation of the viral core enhances the fusion of HIV-1 particles with primary human T cells and monocyte-derived macrophages. Virology (2005) 1.01
Novel activities of cyclophilin A and cyclosporin A during HIV-1 infection of primary lymphocytes and macrophages. J Immunol (2006) 0.95
Target structures for HIV-1 inactivation by methylene blue and light. J Med Virol (1995) 0.91
Activity of the Mason-Pfizer monkey virus fusion protein is modulated by single amino acids in the cytoplasmic tail. J Virol (2005) 0.80
Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol (2002) 5.20
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
Assembly properties of the human immunodeficiency virus type 1 CA protein. J Virol (2004) 3.09
Mature HIV-1 capsid structure by cryo-electron microscopy and all-atom molecular dynamics. Nature (2013) 2.98
Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol (2004) 2.65
Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex. J Virol (2006) 2.57
Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol (2004) 2.47
Structural convergence between Cryo-EM and NMR reveals intersubunit interactions critical for HIV-1 capsid function. Cell (2009) 2.32
Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. J Virol (2008) 2.30
Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathog (2008) 1.96
Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol (2010) 1.92
Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J Virol (2002) 1.85
Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J Virol (2005) 1.79
Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells. J Virol (2003) 1.72
The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. Retrovirology (2004) 1.70
Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J Biol Chem (2005) 1.66
Disassembly of human immunodeficiency virus type 1 cores in vitro reveals association of Nef with the subviral ribonucleoprotein complex. J Virol (2003) 1.55
The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating. J Virol (2012) 1.52
Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology (2006) 1.38
Cyclophilin A-dependent restriction of human immunodeficiency virus type 1 capsid mutants for infection of nondividing cells. J Virol (2008) 1.30
A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA. J Virol (2007) 1.28
RING domain mutations uncouple TRIM5α restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating. J Virol (2011) 1.23
Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells. J Virol (2005) 1.23
A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41. J Virol (2006) 1.22
Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes. Antimicrob Agents Chemother (2013) 1.18
TRIM5alpha disrupts the structure of assembled HIV-1 capsid complexes in vitro. J Virol (2010) 1.15
Rhesus TRIM5α disrupts the HIV-1 capsid at the inter-hexamer interfaces. PLoS Pathog (2011) 1.15
Structure of the HIV-1 full-length capsid protein in a conformationally trapped unassembled state induced by small-molecule binding. J Mol Biol (2010) 1.14
Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action. Antimicrob Agents Chemother (2004) 1.13
Maturation-dependent human immunodeficiency virus type 1 particle fusion requires a carboxyl-terminal region of the gp41 cytoplasmic tail. J Virol (2007) 1.10
Unclosed HIV-1 capsids suggest a curled sheet model of assembly. J Mol Biol (2012) 1.08
Protease cleavage leads to formation of mature trimer interface in HIV-1 capsid. PLoS Pathog (2012) 1.07
Second-site suppressors of HIV-1 capsid mutations: restoration of intracellular activities without correction of intrinsic capsid stability defects. Retrovirology (2012) 1.06
Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology (2013) 1.03
Structural insight into HIV-1 capsid recognition by rhesus TRIM5α. Proc Natl Acad Sci U S A (2012) 1.03
Selective restriction of Nef-defective human immunodeficiency virus type 1 by a proteasome-dependent mechanism. J Virol (2006) 1.02
Nef enhances HIV-1 infectivity via association with the virus assembly complex. Virology (2008) 1.01
Anti-HIV activity of defective cyanovirin-N mutants is restored by dimerization. J Biol Chem (2010) 1.01
Maturation of the viral core enhances the fusion of HIV-1 particles with primary human T cells and monocyte-derived macrophages. Virology (2005) 1.01
In vitro uncoating of HIV-1 cores. J Vis Exp (2011) 1.00
Maturation-induced cloaking of neutralization epitopes on HIV-1 particles. PLoS Pathog (2011) 0.99
Structural insights into the anti-HIV activity of the Oscillatoria agardhii agglutinin homolog lectin family. J Biol Chem (2012) 0.94
The NTD-CTD intersubunit interface plays a critical role in assembly and stabilization of the HIV-1 capsid. Retrovirology (2013) 0.92
Analysis of HIV-1-X4 fusion with immature dendritic cells identifies a specific restriction that is independent of CXCR4 levels. J Invest Dermatol (2006) 0.90
Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes. Neoplasia (2013) 0.89
Retrovirus restriction by TRIM5 proteins requires recognition of only a small fraction of viral capsid subunits. J Virol (2013) 0.83
INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo. Retrovirology (2013) 0.79
HIV Nuclear Entry: Clearing the Fog. Viruses (2010) 0.77
Immunology: TRIM5 does double duty. Nature (2011) 0.76